Samuel S. McCachren

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Jithendra Kini Bailur, Samuel S. McCachren, Deon B. Doxie et al. · JCI Insight · 2019 · 163 citations · Full text

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

Noffar Bar, Federica Costa, Rituparna Das et al. · JCI Insight · 2020 · 61 citations · Full text

Immunology, Immunoediting, Pathology +20

Risk-associated alterations in marrow T cells in pediatric leukemia

Jithendra Kini Bailur, Samuel S. McCachren, Katherine E. Pendleton et al. · JCI Insight · 2020 · 61 citations · Full text

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

M. Hope Robinson, Nancy Villa, David L. Jaye et al. · Journal of Clinical Investigation · 2023 · 43 citations · Full text

Cancer Immunosurveillance, T-regulatory Cell, Immunology +14